Market revenue in 2021 | USD 1.7 million |
Market revenue in 2032 | USD 8.9 million |
Growth rate | 16.1% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 29.41% in 2021. Horizon Databook has segmented the Brazil myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
Brazil is anticipated to be the most lucrative market for MG treatment products in Latin America. This dominance can be attributed to high diagnosis rate and easy access to better healthcare facilities in comparison with other Latin American countries.
Furthermore, according to a study published by Frontiers in Neurology, in September 2020, during COVID-19 pandemic, majority of MG patients hospitalized for COVID-19 were in critical condition.
As per the same source, around 87% were admitted to the ICU, around 73% required mechanical ventilation, and around 30% died. The use of immunoglobulin and plasma exchange was safe in these patients, and immunosuppressive therapy appears to be associated with more favorable outcomes.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Brazil myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account